Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Tumor Lysis SyndromeCancerHyperuricemia
Interventions
DRUG

Rasburicase (SR29142)

30-min IV infusion

DRUG

Allopurinol

Oral administration

Trial Locations (15)

10595

New York Medical College, Valhalla

11215

New York Methodist Hospital, Brooklyn

14263

Roswell Park Cancer Institute, Buffalo

14642

University of Rochester Medical Center, Rochester

19194

University of Pennsylvania Health Systems, Philadelphia

27710

Duke University Medical Center, Durham

32209

University of Florida Health Science Center at Jacksonville, Jacksonville

70121

Ochsner Clinic Foundation, New Orleans

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Rocky Mountain Cancer Center, Denver

90095

UCLA Medical Center, Los Angeles

94704

Alta Bates Comprehensive Cancer Center, Berkeley

97201

Oregon Health and Sciences University, Portland

02114

Massachusetts General Hospital, Boston

26506-9162

Mary Babb Randolph Cancer Center, Morgantown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY